| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Charanraj Goud Alladi, Ravi Philip RajKumar, Surendiran Adithan, Cynthia Marie-Claire, Frank Bellivier, Deepak Gopal Shewad. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia. Fundamental & clinical pharmacology. vol 33. issue 3. 2019-09-16. PMID:30332506. |
dopamine (drd2) and serotonin (htr2a, 2c) receptor gene polymorphisms do not influence early response to risperidone in south indian patients with schizophrenia. |
2019-09-16 |
2023-08-13 |
Not clear |
| F Tollens, N Gass, R Becker, A J Schwarz, C Risterucci, B Künnecke, P Lebhardt, J Reinwald, M Sack, W Weber-Fahr, A Meyer-Lindenberg, A Sartoriu. The affinity of antipsychotic drugs to dopamine and serotonin 5-HT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 9. 2019-05-03. PMID:30006253. |
therefore, we examined the relationship between the affinities of three second-generation antipsychotics (amisulpride, risperidone and olanzapine) to dopamine and serotonin receptors and fc patterns related to the prefrontal cortex (pfc) and striatum in sprague-dawley rats. |
2019-05-03 |
2023-08-13 |
rat |
| Magdalena Kolasa, Joanna Solich, Agata Faron-Górecka, Dariusz Żurawek, Paulina Pabian, Sylwia Łukasiewicz, Maciej Kuśmider, Kinga Szafran-Pilch, Marta Szlachta, Marta Dziedzicka-Wasylewsk. Paroxetine and Low-dose Risperidone Induce Serotonin 5-HT Neuroscience. vol 377. 2019-03-11. PMID:29544901. |
paroxetine and low-dose risperidone induce serotonin 5-ht recently, it has been shown that serotonin 5-ht |
2019-03-11 |
2023-08-13 |
Not clear |
| K K Fjukstad, A Engum, S Lydersen, I Dieset, N Eiel Steen, O A Andreassen, O Spigse. Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics. European psychiatry : the journal of the Association of European Psychiatrists. vol 48. 2018-12-18. PMID:29331603. |
the aim of this observational study was to investigate the relationship between metabolic factors and use of selective serotonin reuptake inhibitors (ssris) combined with olanzapine, quetiapine or risperidone. |
2018-12-18 |
2023-08-13 |
Not clear |
| Katarzyna Kamińska, Anna Górska, Karolina Noworyta-Sokołowska, Adam Wojtas, Zofia Rogóż, Krystyna Gołembiowsk. The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. Pharmacological reports : PR. vol 70. issue 5. 2018-11-16. PMID:30144663. |
the effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. |
2018-11-16 |
2023-08-13 |
rat |
| Hongying Chen, Yong Fan, Lei Zhao, Yong Hao, Xiajun Zhou, Yangtai Guan, Zezhi L. Successful treatment with risperidone increases 5-HT 3A receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. Brain and behavior. vol 7. issue 9. 2018-07-16. PMID:28948091. |
successful treatment with risperidone increases 5-ht 3a receptor gene expression in patients with paranoid schizophrenia - data from a prospective study. |
2018-07-16 |
2023-08-13 |
Not clear |
| K Kaminska, Z Rogo. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. vol 67. issue 3. 2017-05-09. PMID:27512008. |
several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (ssri), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. |
2017-05-09 |
2023-08-13 |
rat |
| K Kaminska, Z Rogo. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. vol 67. issue 3. 2017-05-09. PMID:27512008. |
way 100635 (a serotonin 5-ht1a receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. |
2017-05-09 |
2023-08-13 |
rat |
| Aditya Hegde, Bangalore G Kalyani, Shyam Sundar Arumugham, Janardhanan C Narayanaswamy, Suresh Bada Math, Y C Janardhan Redd. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. Journal of clinical psychopharmacology. vol 36. issue 4. 2017-04-12. PMID:27219093. |
patients with ocd initiated on risperidone augmentation without concurrent cognitive behavior therapy and who were on stable and adequate doses of serotonin reuptake inhibitors for at least 12 preceding weeks were included for analysis. |
2017-04-12 |
2023-08-13 |
Not clear |
| Aditya Hegde, Bangalore G Kalyani, Shyam Sundar Arumugham, Janardhanan C Narayanaswamy, Suresh Bada Math, Y C Janardhan Redd. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. Journal of clinical psychopharmacology. vol 36. issue 4. 2017-04-12. PMID:27219093. |
the study demonstrated, in a real-world setting, that risperidone may be a useful augmenting agent in a proportion of patients with partial/poor response to serotonin reuptake inhibitors. |
2017-04-12 |
2023-08-13 |
Not clear |
| Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowsk. Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological reports : PR. vol 69. issue 1. 2017-03-23. PMID:27755991. |
it was demonstrated that co-administration of risperidone and selective serotonin reuptake inhibitors alleviated depressive symptoms and cognitive dysfunction in animal models of schizophrenia. |
2017-03-23 |
2023-08-13 |
rat |
| Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowsk. Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological reports : PR. vol 69. issue 1. 2017-03-23. PMID:27755991. |
moreover, combination of fluoxetine or mirtazapine with risperidone increased da and 5-hydroxytryptamine (5-ht) release in the rat frontal cortex more potently than either drug given separately. |
2017-03-23 |
2023-08-13 |
rat |
| Katarzyna Kamińska, Karolina Noworyta-Sokołowska, Alexandra Jurczak, Anna Górska, Zofia Rogóż, Krystyna Gołembiowsk. Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects. Pharmacological reports : PR. vol 69. issue 1. 2017-03-23. PMID:27755991. |
the present study aimed to investigate whether combination of risperidone and escitalopram is effective in increasing da and 5-ht release. |
2017-03-23 |
2023-08-13 |
rat |
| Jiamei Lian, Bo Pan, Chao Den. Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological reports : PR. vol 68. issue 5. 2017-03-20. PMID:27428765. |
this study aimed to investigate the effects of aripiprazole, olanzapine and risperidone on the binding of serotonin (5-ht) and dopamine receptors in juvenile rat brain regions that are involved in antipsychotic efficacy. |
2017-03-20 |
2023-08-13 |
rat |
| Amilton dos Santos Júnior, Taciane Barbosa Henriques, Maricilda Palandi de Mello, Adriana Perez Ferreira Neto, Lúcia Arisaka Paes, Osmar Henrique Della Torre, Letícia Esposito Sewaybricker, Thiago Salum Fontana, Eloisa Helena Rubello Valler Celeri, Gil Guerra Júnior, Paulo Dalgalarrond. Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. Journal of child and adolescent psychopharmacology. vol 25. issue 10. 2016-10-05. PMID:26682995. |
the aim of this study was to evaluate the frequency of hyperprolactinemia in children and adolescents treated with risperidone, and its associations with clinical and pharmacological data and certain polymorphisms of the following genes: dopamine receptor d2 (drd2), 5-hydroxytryptamine (serotonin) receptor 2c (htr2c), cytochrome p450, family 2, subfamily d, polypeptide 6 (cyp2d6), leptin (lep), leptin receptor (lepr), melanocortin 4 receptor (mc4r), and scavenger receptor class b, member 2 (scarb2). |
2016-10-05 |
2023-08-13 |
Not clear |
| Serena Deiana, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riede. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behavioural pharmacology. vol 26. issue 8 Spec No. 2016-08-22. PMID:26287433. |
collectively, the combined activity of aripiprazole on dopamine d2 and serotonin 5ht1a receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. |
2016-08-22 |
2023-08-13 |
human |
| Shigeru Hasebe, Yukio Ago, Saki Nishiyama, Satoshi Oka, Hitoshi Hashimoto, Kazuhiro Takuma, Toshio Matsud. Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice. Behavioural pharmacology. vol 26. issue 7 Spec No. 2016-05-25. PMID:25932719. |
encounter-induced hyperactivity was reduced by acute administration of various antidepressants including the tricyclic antidepressant desipramine (10 mg/kg), the selective serotonin (5-ht) reuptake inhibitors fluvoxamine (10 mg/kg) and paroxetine (10 mg/kg), the 5-ht/noradrenaline reuptake inhibitors venlafaxine (10 mg/kg) and duloxetine (10 mg/kg), the antipsychotic drug risperidone (0.01 mg/kg), the 5-ht2 antagonist ritanserin (1 mg/kg), and the glucocorticoid receptor antagonist ru-43044 (30 mg/kg). |
2016-05-25 |
2023-08-13 |
mouse |
| Sabri Hergüner, Hatice Yardım Özayhan, Emire Aybuke Erdu. Risperidone-induced Gingival Bleeding in a Pediatric Case: A Dose-dependent Side Effect. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 14. issue 2. 2016-04-30. PMID:27121433. |
the bleeding side effect of risperidone might be caused by several mechanisms, including 5-hydroxytryptamine 2a receptor antagonism. |
2016-04-30 |
2023-08-13 |
Not clear |
| Yen-Feng Lee, Chia-Kuang Tsai, Chih-Sung Lian. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation. Clinical neuropharmacology. vol 38. issue 4. 2016-04-11. PMID:26166241. |
high-dose risperidone treatment is the most probable cause, and the mechanisms may be related to risperidone's high affinity for the 5-hydroxytryptamine 2a and dopamine 2 receptors. |
2016-04-11 |
2023-08-13 |
Not clear |
| Maria Corena-McLeo. Comparative Pharmacology of Risperidone and Paliperidone. Drugs in R&D. vol 15. issue 2. 2016-03-25. PMID:25943458. |
although risperidone shows higher affinity for 5-ht receptors, paliperidone does not fit this profile. |
2016-03-25 |
2023-08-13 |
rat |